Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R. Karachaliou N, et al. Among authors: teixido c. Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29383037 Free PMC article.
Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.
Pesántez D, Indacochea A, Angelats L, Sirico M, Victoria I, Sanfeliu E, Teixido C, González-Navarro AE, Galván P, Brasó-Maristany F, Jares P, Juan M, Prat A, Schettini F, García-Corbacho J. Pesántez D, et al. Among authors: teixido c. JCO Precis Oncol. 2023 Sep;7:e2300051. doi: 10.1200/PO.23.00051. JCO Precis Oncol. 2023. PMID: 37856765 No abstract available.
Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
Duch P, Díaz-Valdivia N, Gabasa M, Ikemori R, Arshakyan M, Fernández-Nogueira P, Llorente A, Teixido C, Ramírez J, Pereda J, Chuliá-Peris L, Galbis JM, Hilberg F, Reguart N, Radisky DC, Alcaraz J. Duch P, et al. Among authors: teixido c. Cancer Sci. 2024 May;115(5):1505-1519. doi: 10.1111/cas.16141. Epub 2024 Mar 12. Cancer Sci. 2024. PMID: 38476010 Free PMC article.
Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after BRAF and NRAS mutation characterisation: a single institution experience.
Moysset I, Castrejon N, Garcia-Herrera A, Castillo P, Marginet M, Teixido C, Podlipnik S, Albero-Gonzalez R, Montironi C, Navarro J, Rovira C, Puig S, Carrera C, Alos L. Moysset I, et al. Among authors: teixido c. Histopathology. 2024 Jun;84(7):1154-1166. doi: 10.1111/his.15160. Epub 2024 Feb 26. Histopathology. 2024. PMID: 38409889
TAZ is highly expressed in gastric signet ring cell carcinoma.
Yue G, Sun X, Gimenez-Capitan A, Shen J, Yu L, Teixido C, Guan W, Rosell R, Liu B, Wei J. Yue G, et al. Among authors: teixido c. Biomed Res Int. 2014;2014:393064. doi: 10.1155/2014/393064. Epub 2014 Feb 24. Biomed Res Int. 2014. PMID: 24707483 Free PMC article.
Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.
Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Teixidó C, et al. Transl Lung Cancer Res. 2014 Apr;3(2):70-4. doi: 10.3978/j.issn.2218-6751.2014.02.02. Transl Lung Cancer Res. 2014. PMID: 25806283 Free PMC article. Review.
ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B, Vergnenegre A, de Marinis F, Molina MA, Teixido C, Rosell R. Karachaliou N, et al. Among authors: teixido c. Transl Lung Cancer Res. 2014 Jun;3(3):122-30. doi: 10.3978/j.issn.2218-6751.2014.03.02. Transl Lung Cancer Res. 2014. PMID: 25806291 Free PMC article.
A critical question for cancer therapy: what new targets exist?
Rosell R, Karachaliou N, Codony J, Teixido C, Garcia-Roman S, Morales D, Cao MG, Viteri S, Veliz I, Loo Y, Castillo O. Rosell R, et al. Among authors: teixido c. Transl Lung Cancer Res. 2014 Dec;3(6):384-8. doi: 10.3978/j.issn.2218-6751.2014.08.10. Transl Lung Cancer Res. 2014. PMID: 25806328 Free PMC article.
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. Scheffler M, et al. Among authors: teixido c. Oncotarget. 2015 Apr 30;6(12):10577-85. doi: 10.18632/oncotarget.3387. Oncotarget. 2015. PMID: 25868855 Free PMC article.
93 results